questionsmedicales.fr
Hémopathies et maladies lymphatiques
Hémopathies
Maladies de la moelle osseuse
Maladies de la moelle osseuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
Multicenter Studies as Topic
Diagnostic
5
Biopsie de la moelle osseuse
Anémie
Leucémie
Aspirations de moelle osseuse
Tests génétiques
Hématologie
Fatigue
Infections
Saignements
Imagerie par résonance magnétique
Tomodensitométrie
Moelle osseuse
Tests sanguins
Anomalies sanguines
Hématologie
Symptômes
5
Fatigue
Fièvre
Douleurs osseuses
Système immunitaire
Globules blancs
Immunodéficience
Saignements
Plaquettes
Hémorragie
Douleurs osseuses
Infiltration
Cellules anormales
Types de maladies
Symptômes
Hématologie
Prévention
5
Prévention
Mode de vie sain
Hérédité
Facteurs de risque
Produits chimiques
Toxiques
Alimentation
Santé
Moelle osseuse
Tabagisme
Facteurs de risque
Maladies hématologiques
Examens réguliers
Prévention
Anomalies
Traitements
5
Chimiothérapie
Radiothérapie
Greffe de moelle osseuse
Greffe de moelle osseuse
Efficacité
Risques
Médicaments
Immunosuppresseurs
Facteurs de croissance
Radiothérapie
Cancer
Moelle osseuse
Traitements personnalisés
Type de maladie
Gravité
Complications
5
Complications
Infections
Insuffisance médullaire
Cancer
Risque
Maladies de la moelle osseuse
Infections
Immunodéficience
Moelle osseuse
Saignements
Plaquettes
Graves
Insuffisance médullaire
Anémie
Hémorragies
Facteurs de risque
5
Facteurs de risque
Radiations
Antécédents familiaux
Âge
Risque
Maladies de la moelle
Maladies auto-immunes
Risque
Moelle osseuse
Mode de vie
Tabagisme
Risque
Infections virales
VIH
Risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Maladies de la moelle osseuse : Questions médicales les plus fréquentes",
"headline": "Maladies de la moelle osseuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Maladies de la moelle osseuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-15",
"dateModified": "2025-04-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Maladies de la moelle osseuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hémopathies",
"url": "https://questionsmedicales.fr/mesh/D006402",
"about": {
"@type": "MedicalCondition",
"name": "Hémopathies",
"code": {
"@type": "MedicalCode",
"code": "D006402",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Aplasies médullaires",
"alternateName": "Bone Marrow Failure Disorders",
"url": "https://questionsmedicales.fr/mesh/D000080983",
"about": {
"@type": "MedicalCondition",
"name": "Aplasies médullaires",
"code": {
"@type": "MedicalCode",
"code": "D000080983",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.223"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anémie aplasique",
"alternateName": "Anemia, Aplastic",
"url": "https://questionsmedicales.fr/mesh/D000741",
"about": {
"@type": "MedicalCondition",
"name": "Anémie aplasique",
"code": {
"@type": "MedicalCode",
"code": "D000741",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.223.250"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Maladies myélodysplasiques-myéloprolifératives",
"alternateName": "Myelodysplastic-Myeloproliferative Diseases",
"url": "https://questionsmedicales.fr/mesh/D054437",
"about": {
"@type": "MedicalCondition",
"name": "Maladies myélodysplasiques-myéloprolifératives",
"code": {
"@type": "MedicalCode",
"code": "D054437",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.615"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myélomonocytaire juvénile",
"alternateName": "Leukemia, Myelomonocytic, Juvenile",
"url": "https://questionsmedicales.fr/mesh/D054429",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myélomonocytaire juvénile",
"code": {
"@type": "MedicalCode",
"code": "D054429",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.615.520"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Syndromes myélodysplasiques",
"alternateName": "Myelodysplastic Syndromes",
"url": "https://questionsmedicales.fr/mesh/D009190",
"about": {
"@type": "MedicalCondition",
"name": "Syndromes myélodysplasiques",
"code": {
"@type": "MedicalCode",
"code": "D009190",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.625"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anémie réfractaire",
"alternateName": "Anemia, Refractory",
"url": "https://questionsmedicales.fr/mesh/D000753",
"about": {
"@type": "MedicalCondition",
"name": "Anémie réfractaire",
"code": {
"@type": "MedicalCode",
"code": "D000753",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.625.062"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anémie réfractaire avec excès de blastes",
"alternateName": "Anemia, Refractory, with Excess of Blasts",
"url": "https://questionsmedicales.fr/mesh/D000754",
"about": {
"@type": "MedicalCondition",
"name": "Anémie réfractaire avec excès de blastes",
"code": {
"@type": "MedicalCode",
"code": "D000754",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.625.062.080"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anémie réfractaire avec excès de blastes",
"alternateName": "Anemia, Refractory, with Excess of Blasts",
"url": "https://questionsmedicales.fr/mesh/D000754",
"about": {
"@type": "MedicalCondition",
"name": "Anémie réfractaire avec excès de blastes",
"code": {
"@type": "MedicalCode",
"code": "D000754",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.625.062.080"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anémie sidéroblastique",
"alternateName": "Anemia, Sideroblastic",
"url": "https://questionsmedicales.fr/mesh/D000756",
"about": {
"@type": "MedicalCondition",
"name": "Anémie sidéroblastique",
"code": {
"@type": "MedicalCode",
"code": "D000756",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.625.070"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hémoglobinurie paroxystique",
"alternateName": "Hemoglobinuria, Paroxysmal",
"url": "https://questionsmedicales.fr/mesh/D006457",
"about": {
"@type": "MedicalCondition",
"name": "Hémoglobinurie paroxystique",
"code": {
"@type": "MedicalCode",
"code": "D006457",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.625.460"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Syndromes myéloprolifératifs",
"alternateName": "Myeloproliferative Disorders",
"url": "https://questionsmedicales.fr/mesh/D009196",
"about": {
"@type": "MedicalCondition",
"name": "Syndromes myéloprolifératifs",
"code": {
"@type": "MedicalCode",
"code": "D009196",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.636"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anémie myélophtisique",
"alternateName": "Anemia, Myelophthisic",
"url": "https://questionsmedicales.fr/mesh/D000750",
"about": {
"@type": "MedicalCondition",
"name": "Anémie myélophtisique",
"code": {
"@type": "MedicalCode",
"code": "D000750",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.636.085"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie érythroblastique aigüe",
"alternateName": "Leukemia, Erythroblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D004915",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie érythroblastique aigüe",
"code": {
"@type": "MedicalCode",
"code": "D004915",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.636.276"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Myélofibrose primitive",
"alternateName": "Primary Myelofibrosis",
"url": "https://questionsmedicales.fr/mesh/D055728",
"about": {
"@type": "MedicalCondition",
"name": "Myélofibrose primitive",
"code": {
"@type": "MedicalCode",
"code": "D055728",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.636.765"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Thrombocytose",
"alternateName": "Thrombocytosis",
"url": "https://questionsmedicales.fr/mesh/D013922",
"about": {
"@type": "MedicalCondition",
"name": "Thrombocytose",
"code": {
"@type": "MedicalCode",
"code": "D013922",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.190.636.860"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Maladies de la moelle osseuse",
"alternateName": "Bone Marrow Diseases",
"code": {
"@type": "MedicalCode",
"code": "D001855",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sebastian Berg",
"url": "https://questionsmedicales.fr/author/Sebastian%20Berg",
"affiliation": {
"@type": "Organization",
"name": "Division of Pediatric Radiology, Department of Radiology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany."
}
},
{
"@type": "Person",
"name": "Charlotte Niemeyer",
"url": "https://questionsmedicales.fr/author/Charlotte%20Niemeyer",
"affiliation": {
"@type": "Organization",
"name": "Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany."
}
},
{
"@type": "Person",
"name": "Ioannis Mitroulis",
"url": "https://questionsmedicales.fr/author/Ioannis%20Mitroulis",
"affiliation": {
"@type": "Organization",
"name": "Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Germany (I.M., T.C.)."
}
},
{
"@type": "Person",
"name": "George Hajishengallis",
"url": "https://questionsmedicales.fr/author/George%20Hajishengallis",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Innate Immunity and Inflammation, Department of Basic and Translational Sciences, Penn Dental Medicine, University of Pennsylvania, Philadelphia (G.H.)."
}
},
{
"@type": "Person",
"name": "Triantafyllos Chavakis",
"url": "https://questionsmedicales.fr/author/Triantafyllos%20Chavakis",
"affiliation": {
"@type": "Organization",
"name": "Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Germany (I.M., T.C.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35804404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06365-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Access to rehabilitation after stroke in Brazil (AReA study): multicenter study protocol.",
"datePublished": "2022-12-19",
"url": "https://questionsmedicales.fr/article/36535291",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1758558"
}
},
{
"@type": "ScholarlyArticle",
"name": "Surgical Outcomes of Primary Dermatofibrosarcoma Protuberans: A Retrospective, Multicenter Study.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35933538",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12351-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study Protocol of a Prospective Multicenter Observational Study Evaluating Acute Lower Limb Ischemia.",
"datePublished": "2022-11-05",
"url": "https://questionsmedicales.fr/article/36347128",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2022.09.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study.",
"datePublished": "2022-12-09",
"url": "https://questionsmedicales.fr/article/36494618",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-022-02976-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Hémopathies et maladies lymphatiques",
"item": "https://questionsmedicales.fr/mesh/D006425"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hémopathies",
"item": "https://questionsmedicales.fr/mesh/D006402"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladies de la moelle osseuse",
"item": "https://questionsmedicales.fr/mesh/D001855"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Maladies de la moelle osseuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Maladies de la moelle osseuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Maladies de la moelle osseuse",
"description": "Comment diagnostiquer une maladie de la moelle osseuse ?\nQuels tests sont utilisés pour évaluer la moelle osseuse ?\nQuels signes indiquent une maladie de la moelle osseuse ?\nQuelle imagerie est utilisée pour la moelle osseuse ?\nLes tests sanguins peuvent-ils détecter des maladies de la moelle ?",
"url": "https://questionsmedicales.fr/mesh/D001855?mesh_terms=Multicenter+Studies+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Maladies de la moelle osseuse",
"description": "Quels sont les symptômes courants des maladies de la moelle osseuse ?\nComment la moelle osseuse affecte-t-elle le système immunitaire ?\nLes maladies de la moelle osseuse causent-elles des saignements ?\nPeut-on avoir des douleurs osseuses avec ces maladies ?\nLes symptômes varient-ils selon le type de maladie ?",
"url": "https://questionsmedicales.fr/mesh/D001855?mesh_terms=Multicenter+Studies+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Maladies de la moelle osseuse",
"description": "Peut-on prévenir les maladies de la moelle osseuse ?\nQuels facteurs de risque sont évitables ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe tabagisme influence-t-il les maladies de la moelle ?\nLes examens réguliers aident-ils à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D001855?mesh_terms=Multicenter+Studies+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Maladies de la moelle osseuse",
"description": "Quels traitements sont disponibles pour les maladies de la moelle osseuse ?\nLa greffe de moelle osseuse est-elle efficace ?\nQuels médicaments sont utilisés pour traiter ces maladies ?\nLa radiothérapie est-elle une option de traitement ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D001855?mesh_terms=Multicenter+Studies+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Maladies de la moelle osseuse",
"description": "Quelles complications peuvent survenir avec ces maladies ?\nLes maladies de la moelle osseuse augmentent-elles le risque de cancer ?\nComment les infections sont-elles liées à ces maladies ?\nLes saignements peuvent-ils être graves ?\nQuelles sont les conséquences d'une insuffisance médullaire ?",
"url": "https://questionsmedicales.fr/mesh/D001855?mesh_terms=Multicenter+Studies+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Maladies de la moelle osseuse",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de maladies de la moelle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie peut-il affecter le risque ?\nLes infections virales sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001855?mesh_terms=Multicenter+Studies+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie de la moelle osseuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des analyses sanguines, biopsies et examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la moelle osseuse ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'aspiration de moelle osseuse et des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie de la moelle osseuse ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent fatigue, infections fréquentes et saignements anormaux."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est utilisée pour la moelle osseuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et la tomodensitométrie sont souvent utilisées pour visualiser la moelle."
}
},
{
"@type": "Question",
"name": "Les tests sanguins peuvent-ils détecter des maladies de la moelle ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests sanguins peuvent révéler des anomalies dans les cellules sanguines."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des maladies de la moelle osseuse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, ecchymoses et douleurs osseuses."
}
},
{
"@type": "Question",
"name": "Comment la moelle osseuse affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une moelle osseuse malade peut réduire la production de globules blancs, affaiblissant l'immunité."
}
},
{
"@type": "Question",
"name": "Les maladies de la moelle osseuse causent-elles des saignements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des saignements excessifs en raison d'une faible production de plaquettes."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des douleurs osseuses avec ces maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs osseuses peuvent survenir en raison de l'infiltration de cellules anormales."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de maladie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon le type de maladie de la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies de la moelle osseuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies sont héréditaires, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évitables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition à des produits chimiques toxiques peut réduire le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé de la moelle osseuse et du sang."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les maladies de la moelle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour plusieurs maladies hématologiques."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les maladies de la moelle osseuse ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent chimiothérapie, radiothérapie et greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La greffe de moelle osseuse est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être curative pour certaines maladies, mais comporte des risques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter ces maladies ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les agents immunosuppresseurs et les facteurs de croissance sont utilisés."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle une option de traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter certaines formes de cancer de la moelle."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction du type et de la gravité de la maladie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces maladies ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, saignements et insuffisance médullaire."
}
},
{
"@type": "Question",
"name": "Les maladies de la moelle osseuse augmentent-elles le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies de la moelle osseuse peuvent augmenter le risque de cancers secondaires."
}
},
{
"@type": "Question",
"name": "Comment les infections sont-elles liées à ces maladies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une moelle osseuse défaillante peut entraîner une immunodéficience, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les saignements peuvent-ils être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des saignements graves peuvent survenir en raison d'une faible production de plaquettes."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une insuffisance médullaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'insuffisance médullaire peut entraîner une anémie sévère, des infections et des hémorragies."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à des radiations, des produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de maladies de la moelle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de troubles de la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il affecter le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le VIH, peuvent augmenter le risque de maladies de la moelle."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 10/04/2025
Contenu vérifié selon les dernières recommandations médicales
└─
Aplasies médullaires
Bone Marrow Failure Disorders
D000080983
-
C15.378.190.223
└─
Maladies myélodysplasiques-myéloprolifératives
Myelodysplastic-Myeloproliferative Diseases
D054437
-
C15.378.190.615
└─
Syndromes myélodysplasiques
Myelodysplastic Syndromes
D009190
-
C15.378.190.625
└─
Syndromes myéloprolifératifs
Myeloproliferative Disorders
D009196
-
C15.378.190.636
└─└─
Anémie aplasique
Anemia, Aplastic
D000741
-
C15.378.190.223.250
└─└─
Leucémie myélomonocytaire juvénile
Leukemia, Myelomonocytic, Juvenile
D054429
-
C15.378.190.615.520
└─└─
Anémie réfractaire
Anemia, Refractory
D000753
-
C15.378.190.625.062
└─└─
Anémie sidéroblastique
Anemia, Sideroblastic
D000756
-
C15.378.190.625.070
└─└─
Hémoglobinurie paroxystique
Hemoglobinuria, Paroxysmal
D006457
-
C15.378.190.625.460
└─└─
Anémie myélophtisique
Anemia, Myelophthisic
D000750
-
C15.378.190.636.085
└─└─
Leucémie érythroblastique aigüe
Leukemia, Erythroblastic, Acute
D004915
-
C15.378.190.636.276
└─└─
Myélofibrose primitive
Primary Myelofibrosis
D055728
-
C15.378.190.636.765
└─└─
Thrombocytose
Thrombocytosis
D013922
-
C15.378.190.636.860
└─└─└─
Anémie réfractaire avec excès de blastes
Anemia, Refractory, with Excess of Blasts
D000754
-
C15.378.190.625.062.080
2 publications dans cette catégorie
Affiliations :
Division of Pediatric Radiology, Department of Radiology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Affiliations :
Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Affiliations :
Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Germany (I.M., T.C.).
National Center for Tumor Diseases (NCT), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany (I.M.).
First Department of Internal Medicine, Department of Haematology and Laboratory of Molecular Hematology, Democritus University of Thrace, Alexandroupolis, Greece (I.M.).
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Innate Immunity and Inflammation, Department of Basic and Translational Sciences, Penn Dental Medicine, University of Pennsylvania, Philadelphia (G.H.).
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Affiliations :
Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Germany (I.M., T.C.).
Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, United Kingdom (T.C.).
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Affiliations :
Bone Vascular and Microcirculation Laboratory, Department of Kinesiology, University of Texas at Arlington, Arlington, Texas, USA.
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Affiliations :
Mayo Clinic Rochester, MN, USA.
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Publications dans "Maladies de la moelle osseuse" :
2 publications dans cette catégorie
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Department of Radiology, Te Toka Tumai Auckland (Auckland District Health Board), Grafton, Auckland, New Zealand.
Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Department of Radiology, IMSKE, València, Spain.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Tissue and Tumor Microenvironments Group, The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Institute of Clinical Sciences, Imperial College London, London, UK.
MRC London Institute of Medical Sciences, Imperial College London, London, UK.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Tissue and Tumor Microenvironments Group, The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Institute of Clinical Sciences, Imperial College London, London, UK.
MRC London Institute of Medical Sciences, Imperial College London, London, UK.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Tissue and Tumor Microenvironments Group, The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, Copenhagen Ø DK-2100, Denmark; Sheffield Myeloma Research Team, Department of Oncology and Metabolism, Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK; Mellanby Centre for Bone Research, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK. Electronic address: marta.castillo@sund.ku.dk.
Publications dans "Maladies de la moelle osseuse" :
1 publication dans cette catégorie
Affiliations :
Sheffield Myeloma Research Team, Department of Oncology and Metabolism, Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK; Mellanby Centre for Bone Research, University of Sheffield Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK.
Publications dans "Maladies de la moelle osseuse" :
Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be ...
This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus...
Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated....
ClinicalTrials.gov NCT04128722 . Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours - CHRU Tours): DR190041-TOPGUN French regulatory authorit...
Most of the Brazilian population relies on public healthcare and stroke is a major cause of disability in this country of continental dimensions. There is limited information about access to rehabilit...
To provide comprehensive information about Access to Rehabilitation After discharge from public hospitals in Brazil (AReA study), up to 6 months after stroke....
The present study intends to collect information from 17 public health centers in 16 Brazilian cities in the 5 macroregions of the country. Each center will include 36 participants (...
The study is ongoing. Recruitment started on January 31...
The AReA study will fill a gap in knowledge about access to stroke rehabilitation in the public health system in different Brazilian regions....
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive tumor with a low rate of metastatic disease. Previous series have shown a superiority of Mohs micrographic surgery (MMS) compared with wi...
The purpose of the current study was to examine the outcome of surgical treatment of primary DFSP of the trunk and extremities....
We reviewed 236 patients (115 females, 121 males, mean age 41 ± 15 years) undergoing MMS (n = 81, 34%) or WLE (n = 155, 66%) to treat a primary DFSP. Mean tumor size and follow-up was 4 ± 2 cm and 7 y...
There was no difference (p > 0.05) in patient age, sex, tumor size, negative margin excision, or history of a previous inadvertent excision between patients who underwent WLE and those undergoing MMS....
There was no difference in oncologic outcome comparing MMS with WLE for DFSP outside the head and neck. The goal of treatment for DFSP is to achieve a negative margin, regardless of surgical treatment...
Acute lower limb ischemia (ALI) is a limb- and potentially life-threatening condition which requires urgent evaluation and treatment. Contemporary data on optimal therapy and prognosis of ALI are lack...
The proposed study is a prospective, international, multicenter, observational study on ALI (PROMOTE-ALI) (ClinicalTrials.gov - NCT05138679). Patients with ALI (Rutherford classification grade I -III)...
ALI remains a challenging condition and due to the heterogeneous etiology, clinical presentation and treatment strategies, a large multicenter study on this topic is needed to gain contemporary data o...
As a meaningful subtype of ischemic stroke in Asians, Branch atheromatous disease (BAD)-related stroke is associated with high early neurological deterioration (END) and disability, but is understudie...
BAD-study is a nationwide, multicenter, consecutive, prospective, observational cohort study enrolling patients aged 18-80 years with BAD-related stroke within 72 h after symptom onset. Initial clinic...
BAD-study can provide demographic, clinical, radiological, and prognostic characteristics of BAD-related stroke, and thereby potentially figure out the vascular mechanism of early neurological deterio...
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Epidemiological data on cerebral venous thrombosis in China are still lacking at present on the aspects of incidence, recurrence, risk factors, and so on. Herein, we aimed to fill the gap, based on th...
Rectal cancer is a common cancer worldwide. Surgery for rectal cancer with low anterior resection often includes the formation of a temporary protective loop ileostomy. The temporary ostomy is later r...
The present multicenter, double-blinded, randomized, controlled study will compare standard suture closure of the abdominal wall in loop ileostomy reversal with retromuscular synthetic mesh at the sto...
This double-blinded randomized controlled superiority study will compare retromuscular synthetic mesh during the closure of loop ileostomy to standard care. If this study can show a lower frequency of...
ClinicalTrials.gov NCT03720262. Registered on October 25, 2018....
Multicenter contemporary data describing short-term outcomes after initial interventions of neonates with pulmonary atresia with intact ventricular septum (PA-IVS) are limited. This multicenter study ...
Neonates with PA-IVS who underwent surgical or catheter intervention between 2009 and 2019 in 19 centers were reviewed. Risk factors for MACE, defined as cardiopulmonary resuscitation, mechanical circ...
We reviewed 279 neonates: 79 (28%) underwent right ventricular decompression, 151 (54%) underwent systemic-to-pulmonary shunt or ductal stent placement only, 36 (13%) underwent right ventricular decom...
In a multicenter cohort, 1 in 5 neonates with PA-IVS experienced MACE after their initial intervention. Patients with 2 major coronary artery stenoses or lower weight at the time of the initial proced...
Cases of Toxoplasma reactivation or more severe primary infection have been reported in patients receiving immunosuppressive (IS) treatment for autoimmune diseases (AID). The purpose of this study was...
A multicenter descriptive study was conducted using data from the French National Reference Center for Toxoplasmosis (NRCT) that received DNA extracts or strains isolated from patients, associated wit...
61 cases were collected: 25 retrieved by the NRCT and by a call for observations and 36 from a literature review. Half of the cases were attributed to reactivation (50.9%), and most of cases (49.2%) w...
Although this remains a rare condition, clinicians should be aware for the management of patients and for the choice of IS treatment....